Abstract. The identification of novel biomarkers is of great importance for improving the outcome of patients with non-small cell lung cancer (NSCLC). Therefore, the aim of the present study was to determine whether the serum transthyretin (TTR) level could be used as a novel prognostic biomarker for patients with NSCLC. Serum TTR levels, and nutritional and inflammatory parameters were examined prior to treatment in 42 patients with NSCLC. Candidates for independent predictors of prognostic factors were subjected to univariate and multivariate analyses using a Cox proportional hazard model. IL-12-productivity, serum retinol binding protein, albumin and transferrin levels, and lymphocyte-to-monocyte ratio were significantly lower in the patients with TTR <22 mg/dl than those in the patients with TTR ≥22 mg/dl. Patients with serum TTR levels of <22 mg/dl exhibited a poorer overall (P=0.008) and recurrence-free survival (P=0.027) when compared with those with serum TTR levels of ≥22 mg/dl. The parameters, ≥T2 and age ≥75 years were independent prognostic factors for overall survival, and TTR <22 mg/dl and ≥T2 were independent prognostic factors for recurrence-free survival. In conclusion, anthropometric measurement of serum TTR, as well as T category, can be useful for predicting the 5-year recurrence-free survival of patients with NSCLC.
Introduction
Lung cancer is the leading cause of cancer death worldwide, accounting for 19.4% of cancer deaths in adults (1) . It is essentially divided into two types: Small-cell lung cancer (approximately 15%) and non-small cell lung cancer (NSCLC) (approximately 85%). Despite advances in early detection and standard treatment, NSCLC is still often diagnosed at an advanced stage and has a poor prognosis (2) .
In search of a biomarker to predict the prognosis of NSCLC patients, there has been accumulating evidence reported of the usefulness of inflammation-or nutritional factor-based prognostic scores, such as the Glasgow prognostic score (GPS) based on C-reactive protein (CRP) and albumin (3) . Previously, we reported significance of the high-sensitivity modified GPS in patients with resectable NSCLC (4) . However, as these scoring systems require calculation using several variables, a simpler preoperative prognostic biomarker is needed.
Transthyretin (TTR), also known as prealbumin, has a relatively short half-life (approximately two days), and is the earliest laboratory indicator of malnutrition status because it contains a high percentage of essential amino acids (5) . TTR correlates with patient outcome in various diseases (6) (7) (8) . With regard to lung cancer, TTR has been reported to be useful in distinguishing lung cancer from lung infection (9) , and to be synthesized in lung cancer cells (10) . Low perioperative serum TTR was reported to predict early recurrence after curative-intent surgery in NSCLC patients (11) . Although Alifano et al (12) reported that TTR was useful to predict prognosis of NSCLC patients in relation to CRP and CD8+ lymphocyte, its prognostic value remains to be determined. Thus, we sought to examine the preoperative prognostic impact of serum TTR in patients with NSCLC in relation to other nutritional and inflammatory factors.
Patients and methods
Study population. Forty-two NSCLC patients were prospectively enrolled between September, 2011 and September, 2012 (25 men and 17 women, mean age 68.3; range 50 to 85 years, 24 patients with adenocarcinoma and 18 patients with squamous cell carcinoma). Patient characteristics are summarized in Table I As for the immunological cytokines, the productivity of interleukin (IL)-10, 12, and 17 were examined. Peripheral blood mononuclear cells were separated on Ficoll-Hypaque (Pharmacia-Biotech, Uppsala, Sweden) columns, and washed twice with Roswell Park Memorial Institute media (RPMI)-1640 (Wako Pure Chemical Industries Ltd., Osaka, Japan). The isolated PBMCs were then incubated in one ml of RPMI-1640 at a concentration of 10 6 cells/ml with 10% heat-inactivated fetal calf serum (Gibco BRL, St. Louis, MO, USA) in 5% CO 2 at 37˚C for 24 h with the following stimulations: 20 µg/ml phytohemagglutinin for IL-10 and IL-17 production assays, and 0.01% of Staphylococcus aureus cowan-1 for IL-12 production assays. Aliquots of these supernatants were then frozen and stored at -80˚C until use. Supernatant samples were subsequently thawed and used for the measurement of IL-10, IL-12, and IL-17 concentrations using enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). Each sample was used only once after thawing, and not all blood samples were of sufficient volume for all measurements.
Statistical analysis. Data are presented as frequencies or percentages for categorical variables and mean ± standard deviation for continuous variables, unless otherwise indicated. For categorical clinical variables, differences between two groups were evaluated by chi-square test or Fisher's exact test. The differences in mean values between the groups were analyzed using the Mann-Whitney U test. One-way analysis of variance was used for comparisons of variables between more than two groups with Tukey's post hoc test for multiple comparisons. Associations between the two variables were quantified using Spearman's rank correlation coefficient.
With regard to survival analysis, the mean observation period was 67.9 months (range: 60.6-73.8). The final assessment of disease status was made on September 30, 2017. The overall survival rate was calculated using the Kaplan-Meier method and differences between the groups were assessed using the log-rank test. The TTR cutoff value for evaluation as a prognostic factor was set at 22 mg/dl according to its normal range (≥22 mg/dl) at our institution. According to our previous study (4) the albumin, CRP and NLR cutoff values, were set at 3.5 g/dl, 0.3 mg/dl and 4.5, respectively. Prognostic factor candidates were subjected to univariate and multivariate analysis using a Cox proportional hazard model to identify independent predictors of prognosis. When a P-value of a factor was under 0.05 in the univariate analysis, the factor was also analyzed in the multivariate analysis. A two-sided P<0.05 was considered to indicate a statistically significant difference. All statistical calculations were performed using SPSS version 24 software (IBM, Corp., Armonk, NY, USA). 
Results

Relationship between TTR and clinicopathological features.
As shown in Fig. 1 , serum TTR levels exhibited significant correlations with serum albumin (r= 0.710, P<0.001), RBP (r= 0.792, P<0.001), TF (r=0.480, P=0.002) and LMR (r=0.391, P=0.010), but also showed significantly inverse correlations with age (r=-0.606, P<0.001), CRP (r=-0.414, P=0.007) and NLR (r=-0.341, P=0.027). When TTR levels were compared with T categories (T4 was excluded due to its small number), T categories had a statistically significant effect on TTR levels using one-way ANOVA {F (2, 37)=6.533, P=0.004} ( Fig. 2A) . In an analysis of the post hoc test using Turkey's method, TTR levels of the patients with T3 showed statistically lower than those with T1 (P=0.003) or T2 (P=0.005). In addition, IL-12-productivity, serum RBP, albumin and TF levels, and LMR were significantly lower in the patients with TTR <22 mg/dl than those in the patients with TTR ≥22 mg/dl (Fig. 2B) . Table II . The mean age of the patients with TTR <22 mg/dl (66.6±9.0 years) was significantly higher than that of the patients with TTR ≥22 mg/dl (75.0±7.7 years) (P= 0.005). In addition, the incidence of abnormal CEA levels, albumin <3.5 mg/dl and CRP >0.3 mg/dl was significantly higher in the patients with TTR <22 mg/dl than in the patients with TTR ≥22 mg/dl (P= 0.042, 0.004 and 0.022, Figure 2 . Associations between serum TTR and clinicopathological features. (A) When the TTR levels were compared with T categories (T4 was excluded due to its small number), the T categories were revealed to have a statistically significant effect on TTR levels as determined by one-way analysis of variance {F (2, 37)=6.533, P=0.004}. Furthermore, following post hoc Tukey test comparisons, the TTR levels of the patients with T3 were significantly lower than those with T1 (P= 0.003) or T2 (P= 0.005). (B) IL-12-productivity (P= 0.002), serum RBP (P<0.001), albumin (P<0.001) and transferrin levels (P= 0.011) and LMR (P= 0.042) were significantly lower in the patients with TTR <22 mg/dl than those in the patients with TTR ≥22 mg/dl. TTR, transthyretin; IL-12, interleukin-12; RBP, retinol binding protein; LMR, lymphocyte-to-monocyte ratio. respectively). There were no other significant differences in the demographics between the patients with TTR ≥22 mg/dl and TTR <22 mg/dl. Regarding the operated 35 patients, the mean age of the patients with TTR <22 mg/dl (74.9±8.6 years) was higher than that of the patients with TTR ≥22 mg/dl (67.4±8.8 years) (P= 0.031), and the incidence of abnormal CEA levels, albumin <3.5 mg/dl and CRP >0.3 mg/dl was significantly higher in the patients with TTR <22 mg/dl than TTR≥22  TTR<22  P-value  TTR≥22  TTR<22  P- TTR, transthyretin (mg/dl); Adeno, adenocarcinoma; Squamous, squamous cell carcinoma; Size, tumor size (mm); CEA, carcinoembryonic antigen (ng/ml); SCC, squamous cell carcinoma antigen (ng/ml); Cyfra, cytokeratin-19 fragment (ng/ml); ALB, albumin (g/dl); CRP, C-reactive protein (mg/dl); NLR, neutrophil-to-lymphocyte ratio; Ly, lymphatic vessel invasion; V, blood vessel invasion; NA, not applicable.
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in the patients with TTR ≥22 mg/dl (P= 0.034, 0.006 and 0.007, respectively). Fig. 3A shows overall survival and Fig. 3B shows recurrence-free survival of the patients. The patients with TTR <22 mg/dl (P= 0.008), the patients with T ≥2, and the patients who were aged 75 years or older showed significantly poorer overall prognoses (Fig. 3A) . Furthermore, the patients with TTR <22 mg/dl (P= 0.027) and those with T ≥2 showed significantly poorer recurrence-free survival rates (Fig. 3B) . Table III shows the results of prognostic factor analysis using a Cox proportional hazard model. TTR <22 mg/dl, ≥T2 and age ≥75 years were statistically significant in the univariate analysis. In the multivariate analysis, ≥T2 (HR=7.161, 95% confidence interval, 1.959-26.172, P=0.003) and age ≥75 years (HR=3.775, 95% confidence interval, 1.098-12.982, P= 0.035) were independent prognostic factors of overall survival. With regard to recurrence-free survival, TTR <22 mg/dl and ≥T2 were statistically significant in the univariate analysis. In the multivariate analysis, TTR <22 mg/dl (HR=3.866, 95% confidence interval, 1.223-12.220, P= 0.021) and ≥T2 (HR=4.035, 95% confidence interval, 1.341-12.143, P= 0.013) were independent prognostic factors of recurrence-free survival.
Discussion
In the present study, the NSCLC patients with serum TTR levels of <22 mg/dl showed a poorer overall and recurrence-free survival than those with serum TTR levels of ≥22 mg/dl. Although TTR <22 mg/dl was not an independent .01. Candidates for independent predictors of prognostic factors (age, <75 vs. ≥75; sex, male vs. female; T, T1 vs. ≥T2; N, negative vs. positive; Ly, negative vs. positive; V, negative vs. positive; ALB, <3.5 mg/dl vs. ≥3.5 mg/dl; CRP, <0.3 mg/dl vs. ≥0.3 mg/dl; NLR: <4.5 vs. ≥4.5; TTR, ≥22 mg/dl vs. <22 mg/dl) were subjected to univariate and multivariate analysis using a Cox proportional hazard model. HR, hazard ratio; 95% CI, 95% confidence interval; T, tumor; N, node; Ly, lymphatic vessel invasion; V, blood vessel invasion; ALB, albumin; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; TTR, transthyretin.
prognostic factor for overall survival, TTR <22 mg/dl was an independent prognostic factors for recurrence-free survival. Alifano et al (12) reported that TTR <28 mg/dl was one of the independent prognostic factors for overall survival in patients with NSCLC. However, they did not assess recurrence-free survival. Moreover, Kawai and Ota (11) reported that preoperative TTR <23 mg/dl and postoperative TTR <15 mg/dl was an independent prognostic factor for 2-year recurrence free survival. Thus, the results of the current study revealed, for the first time, that preoperative TTR was an independent prognostic factor for 5-year recurrence-free survival in NSCLC patients.
The normal function of TTR is to transport thyroxine and RBP/retinol complex in the blood (14) . TTR exists in the blood as a homotetramer and contains four tryptophans which are essential amino acids (5). These characteristics make TTR useful in assessing acute phase nutritional condition. As TTR is also a member of rapid turnover proteins, its level is affected by the presence of infections and inflammation. Therefore, serum albumin in combination with CRP, has been used to evaluate a prognosis of cancer patients (4) . Recently, however, serum TTR level has been reported to be a prognostic biomarker in various malignancies such as esophageal (15) , gastric (16) , colorectal (17) , pancreatic (18) , and renal cancers (19) , as well as lung cancer (11, 12) . Taken together, TTR might be associated with tumor microinflammation, resulting in a poorer prognosis.
With regard to the immunological status in the present study, IL-12 productivity and LMR were lower in the patients with TTR <22 mg/dl. IL-12 is mainly secreted from antigen presenting cells in response to pathogens, promoting CD4+ cell differentiation into Th1 cells, and enhances the cytotoxic ability of both natural killer and CD8+ T cells (20) . On the other hand, lower LMR has been reported to be a useful independent prognostic marker in patients with NSCLC (21). Although higher LMR was firstly reported to be related with favorable prognosis in some hematology malignancies (22) , a low pre-treatment LMR seems to represent an unfavorable prognosis in solid tumors (23) . In the present study, lymphocyte and monocyte counts showed no statistically significant differences between the patients with TTR ≥22 mg/dl and TTR <22 mg/dl, while LMR did exhibit a statistical difference. Taken together, decreased IL-12 productivity and lower LMR represent suppressed anti-tumor immunity in the patients with TTR <22 mg/dl.
A major limitation of the present study is that it includes a small number of NSCLC patients in a retrospective setting. Secondly, not all blood samples were of sufficient volume for all measurements for interleukin productivity. Further research is required to explore the putative association between serum TTR level and prognosis of patients with NSCLS. In conclusion, serum TTR levels, as well as T category, can be useful for predicting the 5-year recurrence-free survival of NSCLC patients. Further studies aimed at discovering nutritional treatments that improve outcomes of patients with NSCLC are warranted.
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